Matrine induces cell apoptosis and necroptosis dependent on RIPKs of lung cancer cells

Xing Lin, Qianshun Chen, Chen Huang, Xunyu Xu

Department of Thoracic Surgery, Provincial Clinical College of Fujian Medical University, Fujian Provincial Hospital, Fuzhou 350001, Fujian, China

Received June 19, 2017; Accepted March 28, 2018; Epub July 15, 2018; Published July 30, 2018

Abstract: Background: Lung cancer is a malignant tumor with high incidence and morality. Matrine is an alkaloid extracted from the dried roots of traditional Chinese medicine Sophora flavescens. In the present study, we aim to explore the antitumor efficiency of matrine in lung cancer cells, as well as its molecular mechanism in lung cancer cell lines. Material & method: The lung cancer cells were treated with increasing concentrations of matrine and cell viability was determined by MTT assay. Cell apoptosis rate and necrosis rate was determined by FACS assay. The levels of RIP-1 and RIP-3 were determined by western blotting analysis. Results: The MTT assay results demonstrated that matrine inhibited the proliferation of A549 and H460 in a time- and dose-dependent manner. Moreover, FACS assay results demonstrated that matrine could enhance cell apoptosis rate and necrosis rate as the increasing concentrations of matrine at 24 hours. Importantly, the matrine-induced cell death could be partly reversed by the pancasepase z-VAD-fmk suggesting that matrine-induced cell apoptosis contributed to the cell death of lung cancer cells. Additionally, western blotting analysis results demonstrated that RIP-1 and RIP-3 levels significantly increased as the increasing concentrations of matrine suggesting matrine promoted the expression of RIP-1 and RIP-3. Conclusion: In conclusion, matrine induced cell apoptosis and necroptosis of lung cancer cells. It has a potential to be used as an effective drug to treat human lung cancers.

Keywords: Matrine, apoptosis, necroptosis, RIP-1, RIP-3

Introduction

Traditional Chinese herbal medicine originated in ancient China, which has evolved over thousands of years [1-3]. It is still used as a major part of healthcare provision in China, which is also used in the clinical therapy for various cancers in China [3-5]. Recently, looking for a safe and effective anticancer drug with little toxic side effects has become the hotspot, which is also helpful in the therapy of cancers. As the development of analysis methods in biochemistry and molecular biology, a large amount of the active compounds was extracted from Chinese Herbal Medicine [6-8]. Matrine is an alkaloid found in plants of the Sophora genus, with the molecular formula of C_{15}H_{24}N_{20}, which is one of the active components and extracted from the dried roots of traditional Chinese medicine Sophora flavescens [9, 10]. A large number of pharmacological and clinical studies have found that matrine has the anti-fibrosis, anti-arrhythmic, immunosuppressive, anti-inflammatory, anti-hypertensive, vascular remodeling, anti-tumor and other pharmacological effects etc [11-15].

Recently, much studies have found matrine induced cell death in vitro and in vivo on a variety of tumor cells. However, the exact molecular mechanism is not clearly clarified till now. Li, H. has found that matrine suppressed cell proliferation of human breast cancer cells by promoting cell apoptosis via upregulation of Bax and downregulation of Bcl-2 [16]. It also reported that matrine inhibited the invasion and metastasis of lung cancer cell by regulating the expression levels of miRNAs, such as elevating expression of miR-133a which further suppressed the activation of EGFR/Akt/MMP-9 pathway [17]. The combination therapy with matrine and platinum-based doublet chemotherapy (PBDC) versus PBDC alone was reported to treat advanced non-small cell lung cancers and the results revealed that matrine combined with PBDC decreased the incidence of
Matrine induces cell apoptosis and necroptosis

adverse reactions compared with PBDC alone [18]. Moreover, an involvement of the NF-kappa B signaling pathway was reported in matrine-treated cancer cells, in which, matrine inhibited the proliferation, invasion and migration of castration-resistant prostate cancer cells by decreasing the levels of P65, p-P65, IKKalpha/beta, p-IKKalpha/beta, IKBalpha and p-IKBalpha [19].

In cancer therapy, one idea is to effectively induce cell death of tumor cells. As we known, programmed cell death, such as apoptosis, autophagy, and necroptosis, played an important role in the development and progression of cancers [20-22]. In the present study, we used human lung cancer cells A549 and H460 as the cell model and explored whether programmed cell death was induced in matrine-treated lung cancer cells. It is helpful to find the new targets in the therapy of lung cancers.

Material and methods

Cell lines and agents

The lung cancer cell lines (A549 and H460) were purchased from American Type Culture Collection (Manassas, VA). The cells were cultured in Dulbecco’s Modified Eagles Medium (DMEM) with 10% fetal bovine serum at 37°C in an atmosphere of 95% air and 5% CO2. DMEM was purchased from Hyclone corporation (Logan, Utah, USA) and FBS was obtained from Gibco Life Technologies. 3-(4,5-Dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (Cat. No. M2128) was purchased from Sigma-Aldrich Corporation (Sigma). Mouse Anti-Human/Mouse/Rat RIPK1/RIP1 monoclonal antibody (Catalog # MAB3585) was purchased from R&D Corporation. RIP-3 Antibody (B-2) is a mouse monoclonal IgG1 provided at 200 µg/ml (Cat. No. sc-374639) and obtained from Santa Cruz corporation. HRP-conjugated anti-mouse IgG secondary antibody (Cat. No. A3682) was also purchased from Santa Cruz Corporation.

MTT assay

Cell viability was determined by MTT assay. The A549 cells and H460 cells were treated with matrine for 24 hours and 48 hours. The concentration of matrine was 0.25 mg/ml, 0.5 mg/ml, 1.0 mg/ml and 2.0 mg/ml. In the other experiment, the lung cancer cells were treated with different concentration of matrine (0.25 mg/ml, 0.5 mg/ml, 1.0 mg/ml and 2.0 mg/ml) in combination with 10 µM of z-VAD-fmk or 0.1% DMSO for 24 hours. Four hours before test, 10 µL of MTT solution (5 mg/ml) was added into the cultured medium and incubated at 37°C in 5% CO2. The absorbance of each well was read at 490 nm.

FACS assay

Annexin V–fluorescein isothiocyanate (FITC)/PI dural staining was used to detect the cell apop-
Matrine induces cell apoptosis and necroptosis

Western blotting assay

The lung cancer cells were treated with different concentrations of matrine (0.25 mg/ml, 0.5 mg/ml, 1.0 mg/ml and 2.0 mg/ml) for 24 hours. The cells were washed with PBS buffer and lysed in RIPA buffer (Cat. No. P0013B, Beyotime, Nanjing, China). 10% SDS-PAGE was used to separate the proteins. Then, the proteins were transferred to PVDF at 400 mA for 1 hour, which was blocked with 5% non-fat milk in TBST buffer. The membrane was incubated with specific primary antibody and followed by HRP-conjugated secondary antibody. Finally, chemiluminescent ECL reagent kit (Millipore) was used for development.

Statistical analysis

SPSS 20.0 software was used to analyze the data (SPSS Inc., Illinois, USA). The multiple comparisons were analyzed by using Two-way ANOVA followed by Tukey test. The others were used two sets of independent samples t-test. All the data was shown as mean values ± S.D. The p<0.05 was considered as statistically different.

Results

Matrine inhibits the proliferation of lung cancer cells in a dose-dependent manner

In order to detect the anti-tumor effects of matrine in human lung cancer cells, we used
Matrine induces cell apoptosis and necroptosis

As shown in Figure 1, the concentrations of matrine were 0.25 mg/ml, 0.5 mg/ml, 1.0 mg/ml and 2.0 mg/ml. A549 cells and H460 cells were treated with different concentrations of matrine for 24 h and 48 h, respectively. The results demonstrated that the inhibition rate of matrine was gradually increased as the increasing concentration of matrine in both 24 hours group and 48 hours group (*p<0.05, **p<0.01, compared with negative control A549 cells; ##p<0.01, compared with negative control H460 cells).

Matrine promotes apoptosis and necroptosis

To further identify the molecular mechanism of matrine in lung cancer cells, FACS assay was performed to determine the cell apoptosis rate and necrosis rate in matrine-treated H460 cells. As shown in Figure 2A, H460 cells were treated with increasing concentrations of matrine for 24 h, and the concentrations of matrine were 0.5 mg/ml, 1.0 mg/ml and 2.0 mg/ml. Moreover, the results of FACS assay demonstrated that the apoptosis and necrosis of H460 was significantly increased compared with the negative control cells (**p<0.01) (Figure 2B). All the results revealed that matrine-induced lung cancer cell death was partly due to the cell apoptosis and cell necrosis.

Caspase inhibitor z-VAD-fmk suppresses matrine-induced cell viability

Z-VAD-fmk is an irreversible general caspase inhibitor to inhibit the activity of caspases. In order to identify whether cell death could be reversed by z-VAD-fmk, the lung cancer cells were treated with increasing concentration of matrine in combination with DMSO or z-VAD-fmk. As shown in Figure 3, the survival rate of A549 and H460 in matrine plus z-VAD-fmk-treated group was higher than that in matrine-treated group, suggesting inhibition cell apoptosis.
Matrine induces cell apoptosis and necroptosis

In order to indentify whether necroptosis was involved in matrine-induced cell death, western blotting analysis was used to determine the levels of RIP-1 and RIP-3 in matrine-treated H460 cells. As shown in Figure 4, H460 cells were treated with various concentration of matrine (0.5 mg/ml, 1.0 mg/ml, 2.0 mg/ml) for 24 hours, and the expression level of RIP-1 and RIP-3 significantly increased in matrine-treated cells. Both RIP-1 and RIP-3 were important kinases in the process of necroptosis and the results demonstrated that matrine could induce the necroptosis in the lung cancer cells.

Discussion

Lung cancer, also known as lung carcinoma, is one of the most common cancers in the world. It is estimated that 174000 Americans are diagnosed as lung cancers each year [24-26]. While in China in 2010, 605900 patients were diagnosed and 486600 patients died of lung cancer [26]. It is an important way to effectively induce cell death of lung cancer cells in cancer therapy. In the present study, we used matrine, the active component in Chinese herbal medicine Sophora to treat lung cancer cells A549 and H460 and explored the molecular mechanism of matrine, which would give some useful clue for the therapy of lung cancers.

Firstly, the lung cancer cells were treated with different concentration of matrine for 24 hours and 48 hours. MTT assay results demonstrated that the inhibition rate significantly decreased as the increasing concentration of matrine. The inhibitory effects in 48 hours were much more obvious than that of 24 hours, which demonstrated that matrine induced the cell death of lung cancer cells in a dose-dependent manner, as well as in a time-dependent manner. All the results revealed that matrine had anti-tumor effects in human lung cancer cells, which was consistent with the results from other researchers [27, 28].

Programmed cell death has three major different ways of cell death, including cell apoptosis, autophagy and necroptosis. Cell apoptosis is a normally seen form of programmed cell death, which is a naturally occurring process in the body and attracted considerable attention in the study of cancerogenesis. Cell autophagy is a self-degradation process which sometimes mediates cell death while sometimes contributes to cell survival [29, 30]. Till now, few studies have focused on cell necroptosis. In the present study, we have identified that matrine promoted cell death of the lung cancer cells. In order to identify whether the cell death is
Matrine induces cell apoptosis and necroptosis

induced by cell apoptosis or necroptosis, we used FACS assay to determine the cell apoptosis rate and necrosis rate. Our results demonstrated that matrine-induced cell apoptosis and necroptosis contributed to the cell death of lung cancer cells, which would be a new drug candidate with little side effects for human lung cancers.

Acknowledgement

The paper is supported by Natural Science Foundation of Fujian Province, Guiding Project, Fund Number 2016Y0012.

Disclosure of conflict of interest

None.

Address correspondence to: Xunyu Xu, Department of Thoracic Surgery, Provincial Clinical College of Fujian Medical University, Fujian Provincial Hospital, 134 East Street, Fuzhou City 350001, Fujian, China; Tel: 0591-87557768; E-mail: xuxunyubest@163.com

References

Matrine induces cell apoptosis and necroptosis


